Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares Global Clean Energy ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while iShares Global Clean Energy ETF trades at $18.96. The key difference: iShares Global Clean Energy ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ICLN | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | — |
52-Week High | $491.22 | $23.75 |
52-Week Low | $278.09 | $13.37 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ICLN trades at $19.25, down 0.41% with a bearish technical signal from moving averages. The ETF shows strong 2026 performance with clean energy sector momentum driven by AI demand and high oil prices. Recent news highlights policy risks from US permit delays affecting $121 billion in renewable investments, while China's 2030 EV targets provide long-term growth catalysts. The fund offers global diversification across 105 clean energy holdings.
Outlook remains cautiously optimistic despite near-term policy headwinds. The structural shift toward clean energy infrastructure and growing global investment support long-term growth potential. Key risks include regulatory uncertainty and competitive pressure from traditional energy ETFs offering higher yields. Current levels may present accumulation opportunities for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
